AU5983900A - Combined preparations comprising antitumor agents - Google Patents

Combined preparations comprising antitumor agents

Info

Publication number
AU5983900A
AU5983900A AU59839/00A AU5983900A AU5983900A AU 5983900 A AU5983900 A AU 5983900A AU 59839/00 A AU59839/00 A AU 59839/00A AU 5983900 A AU5983900 A AU 5983900A AU 5983900 A AU5983900 A AU 5983900A
Authority
AU
Australia
Prior art keywords
antitumor agents
combined preparations
preparations
combined
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59839/00A
Inventor
Michele Caruso
Cristina Geroni
Marina Ripamonti
Antonino Suarato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of AU5983900A publication Critical patent/AU5983900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU59839/00A 1999-07-20 2000-07-10 Combined preparations comprising antitumor agents Abandoned AU5983900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9917012.8A GB9917012D0 (en) 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents
GB9917012 1999-07-20
PCT/EP2000/006540 WO2001005425A2 (en) 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and her2 antibodies

Publications (1)

Publication Number Publication Date
AU5983900A true AU5983900A (en) 2001-02-05

Family

ID=10857596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59839/00A Abandoned AU5983900A (en) 1999-07-20 2000-07-10 Combined preparations comprising antitumor agents

Country Status (5)

Country Link
EP (1) EP1200098A2 (en)
JP (1) JP2003504413A (en)
AU (1) AU5983900A (en)
GB (1) GB9917012D0 (en)
WO (1) WO2001005425A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331646T3 (en) 2000-05-19 2010-01-12 Genentech, Inc. TEST FOR THE DETECTION OF GENES TO IMPROVE THE PROBABILITY OF AN EFFECTIVE ANSWER TO A THERAPY AGAINST CANCER BASED ON ERBB ANTAGONISTS.
GB0114654D0 (en) * 2001-06-15 2001-08-08 Pharmacia & Upjohn Spa Anti-tumor compound
PL1846030T3 (en) 2005-01-21 2019-05-31 Genentech Inc Fixed dosing of her antibodies
UA95902C2 (en) 2005-02-23 2011-09-26 Дженентек, Инк. Extending time to disease progression or survival in cancer patients
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
MA33198B1 (en) 2009-03-20 2012-04-02 Genentech Inc ANTI-HER DI-SPECIFIC ANTIBODIES
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for HER2 signaling in gastric cancer patients expressing HER2
MX2012008958A (en) 2010-02-18 2012-08-23 Genentech Inc Neuregulin antagonists and use thereof in treating cancer.
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN104220457A (en) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (en) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Identification of patients in need of combined therapy with pd-l1 inhibitor
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
PT110526B (en) 2018-01-26 2021-02-04 Univ Nova De Lisboa ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
TW202334221A (en) 2021-11-03 2023-09-01 德商安富美德有限公司 Bispecific cd16a binders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (en) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ATE425749T1 (en) * 1999-01-27 2009-04-15 Cornell Res Foundation Inc TREATMENT OF HER-2/NEW OVEREXPRESSION-ASSOCIATED CANCER
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
DE60040981D1 (en) * 1999-05-14 2009-01-15 Genentech Inc TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Also Published As

Publication number Publication date
JP2003504413A (en) 2003-02-04
WO2001005425A2 (en) 2001-01-25
WO2001005425A3 (en) 2001-05-17
EP1200098A2 (en) 2002-05-02
GB9917012D0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
AU5983900A (en) Combined preparations comprising antitumor agents
AUPQ105499A0 (en) Antiviral agents
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU2002224595A1 (en) Antitumor agents
AU2557600A (en) Skin lightening agents
AU4397700A (en) Combined preparations comprising anthracycline derivatives
AUPQ288499A0 (en) Antiviral agents
AU4090299A (en) Liposomal delivery complex
AU1554301A (en) Radioprotecting agent
AU2451500A (en) Therapeutic agents
AU7446000A (en) Antitumor agents
AU3929799A (en) Effervescent preparations
HUP0200483A3 (en) Liposome preparations
AU2231601A (en) Vancomycin preparations
AU3191100A (en) Ligand-bonded complex
AU1800100A (en) Medicinal preparations
AU2001282521A1 (en) OCT preparations
AU5973600A (en) Therapeutic agents
AU4504201A (en) Drug preparations
AU6150200A (en) Therapeutic agents
AU3158301A (en) Decorative cosmetic preparations
AU3964700A (en) Cosmetic preparations
AU4746300A (en) Cosmetic preparations
AU2824700A (en) Chemically modified g-csf preparations
AU5817400A (en) Therapeutic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase